Analyst Price Target is $65.00
▲ +98.66% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DermTech in the last 3 months. The average price target is $65.00, with a high forecast of $79.00 and a low forecast of $53.00. The average price target represents a 98.66% upside from the last price of $32.72.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in DermTech.
DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.